BioLineRx Posts -$0.38 EPS, $514K Q4 Revenue and Launches GLIX1 Trial
BioLineRx posted EPS of -0.38 in Q4, matching forecasts, and generated revenue of $514,000 versus a $492,000 estimate. The company will initiate a Phase 1/2a GLIX1 glioblastoma trial by end-March 2026, trading at a price-to-sales ratio of 0.84 and debt-to-equity of 0.58.
1. Q4 Financial Results
BioLineRx reported Q4 earnings per share of -0.38, exactly in line with analyst expectations, and delivered $514,000 in revenues, outperforming the $492,000 consensus. The slight revenue beat underscores improving commercial traction despite ongoing R&D expenses.
2. Upcoming GLIX1 Phase 1/2a Trial
The company plans to launch its first-in-human Phase 1/2a trial of GLIX1 for glioblastoma by the end of March 2026, with patient enrollment to follow shortly. GLIX1 targets DNA damage response pathways, aiming to address unmet needs in aggressive brain cancer.
3. Key Financial Ratios
BioLineRx holds a price-to-sales ratio of 0.84, signaling potential undervaluation relative to its sales, while maintaining a debt-to-equity ratio of 0.58. A current ratio of approximately 2.09 indicates sufficient short-term liquidity to support ongoing clinical activities.